- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03161366
Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine
An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Ebola Virus Disease remains ill-known by populations, creating fear and mistrust, is highly contagious, requiring strict isolation measures and with only supportive therapy available that has limited impact on case-fatality which remains high (30 -80%).1 Among vaccines in development, the rVSVΔG-ZEBOV-GP vaccine has given the most promising results in terms of efficacy and safety having been evaluated now in more than 10,000 individuals.
Ring vaccination is a known strategy to control epidemics with specific transmission chains and has been successfully implemented to eradicate smallpox. Ring vaccination enhances standard public health measures of contact tracing, isolation, and community engagement and could be effective when such measures are in place. Building on the interim results of the Ebola ça Suffit trial, there is a need for continued access to a vaccine of which available results suggest that it is safe and likely efficacious against EVD. Although only isolated cases have been reported in Guinea, Sierra Leone and Liberia in 2016, 10 the risk of resurgence or of continued isolated cases in West Africa remains. Moreover, a new outbreak with Ebola Zaïre could start any moment in any of the countries where previous outbreaks occurred as in for example Democratic Republic of Congo and Uganda.
However, the unusual design of the ring trial and the decision to abandon the control group because of strong evidence that the vaccine prevented disease means there may not be enough data to ensure approval from regulatory agencies. Therefore, additional information is still required to consolidate knowledge on the rVSVΔG-ZEBOV-GP vaccine to support regulatory approval and licensure for future access. Additional information is also needed on ring vaccination and contextual adaptations to this approach to ensure its feasibility and effectiveness in the control of Ebola outbreaks in potentially diverse contexts.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kinshasa, Congo, The Democratic Republic of the
- Médecins Sans Frontières
-
-
-
-
-
Mbarara, Uganda, 1956
- Epicentre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals aged 6 years or older will be enrolled in the study if they are a contact or contact of contact of a laboratory-confirmed Ebola virus disease case. Children aged between 1 and 6 years may also be enrolled in the study in case there is a confirmed contact with a laboratory-confirmed Ebola patient
- willing to accept weekly visits
- intending to remain in the study area for three months
- providing informed consent, and where applicable, assent
Exclusion Criteria:
- history of EVD (self-report or laboratory confirmed)
- history of having received other investigational research agents in the previous 28 days
- history of anaphylaxis to a vaccine or vaccine component (self-report)
- severe illness that makes the person bed-bound or requiring hospitalization at the time of the vaccination
- severe immunocompromised status
- history of having received immunosuppressant therapies that would substantially interfere with the mode of action of the Ebola vaccine in the previous 6 months
- unwilling to accept weekly visits
- not intending to remain in the study area for three months
- informed consent or assent not provided
- any other condition in which, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence, or impair the subject or caregiver's ability to give informed consent, and where applicable, assent.
- fever above 38°C
- previous receipt of rVSVΔG-ZEBOV-GP in the last 3 years or at being part of another Ebola vaccine clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
|
Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative incidence
Time Frame: 84 days after vaccination
|
Occurrence of Ebola Zaire cases amongst contacts and contacts of contacts
|
84 days after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Adverse and Serious Adverse Events
Time Frame: 84 days after vaccination
|
Safety of a single dose of rVSVΔG-ZEBOV-GP
|
84 days after vaccination
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- V920-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ebola Virus Disease
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Hemorrhagic Fever | Ebola Virus Vaccines | Envelope Glycoprotein, Ebola Virus | FilovirusUnited States
-
Jiangsu Province Centers for Disease Control and...Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompletedEbola DiseaseSierra Leone
-
Cerus CorporationTerminated
-
National Institute of Allergy and Infectious Diseases...CompletedEbola VirusUnited States, Congo, The Democratic Republic of the
-
National Institute of Allergy and Infectious Diseases...CompletedEbola Virus Disease | Ebola Vaccines | Marburg Virus Disease | Marburgvirus | EbolavirusUnited States
-
London School of Hygiene and Tropical MedicineCompletedHiv | Ebola Virus Disease | EbolaKenya, Uganda
-
Janssen Vaccines & Prevention B.V.Institut National de la Santé Et de la Recherche Médicale, France; University...CompletedEbola Viral DiseaseFrance, United Kingdom
-
MRC/UVRI and LSHTM Uganda Research UnitMinistry of Health, UgandaRecruiting
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsNot yet recruiting
Clinical Trials on rVSVΔG-ZEBOV-GP
-
Cecile TremblayMerck Sharp & Dohme LLC; Dalhousie University; Université de Montréal; Coalition... and other collaboratorsActive, not recruiting
-
Centers for Disease Control and PreventionDepartment of Health and Human Services; University of Sierra Leone; Ministry... and other collaboratorsCompletedHemorrhagic Fever, EbolaSierra Leone
-
National Institute of Allergy and Infectious Diseases...London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaboratorsActive, not recruitingEbola Virus DiseaseGuinea, Liberia, Mali, Sierra Leone
-
Universitätsklinikum Hamburg-EppendorfUniversity Hospital, Geneva; Wellcome Trust; KEMRI-Wellcome Trust Collaborative... and other collaboratorsCompletedHemorrhagic Fever, EbolaGermany
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting
-
Universitätsklinikum Hamburg-EppendorfGoethe University; German Federal Ministry of Education and Research; Bernhard... and other collaboratorsNot yet recruiting
-
Centre de Recherche Médicale de LambarénéMerck Sharp & Dohme LLCCompleted
-
Emory UniversityWashington University School of Medicine; Merck Sharp & Dohme LLCNot yet recruiting
-
Tulane UniversityMerck Sharp & Dohme LLC; Kenema Government HospitalNot yet recruiting
-
Krasnoyarsk Regional HospitalUnknownPathologic Processes | Heart Diseases | Cardiovascular Diseases | Lung Diseases | Atrial Fibrillation | Arrhythmias, Cardiac | Hypertension, Pulmonary